D.E. Shaw & Co
VIR icon

D.E. Shaw & Co’s Vir Biotechnology VIR Stock Holding History

D.E. Shaw & Co’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.33M Buy
817,685
+767,893
+1,542% +$6.12M ﹤0.01% 1876
2025
Q4 		$300K Buy
49,792
+16,268
+49% +$96.9K ﹤0.01% 4151
2025
Q3 		$191K Sell
33,524
-2,733
-8% -$14K ﹤0.01% 4293
2025
Q2 		$183K Sell
36,257
-470,447
-93% -$2.52M ﹤0.01% 4067
2025
Q1 		$3.28M Buy
506,704
+4,704
+0.9% +$41.8K ﹤0.01% 2217
2024
Q4 		$3.68M Sell
502,000
-428,655
-46% -$3.38M ﹤0.01% 2235
2024
Q3 		$6.97M Buy
930,655
+8,101
+0.9% +$70.4K 0.01% 1680
2024
Q2 		$8.21M Buy
922,554
+276,300
+43% +$2.65M 0.01% 1464
2024
Q1 		$6.55M Sell
646,254
-122,890
-16% -$1.25M 0.01% 1681
2023
Q4 		$7.74M Sell
769,144
-111,087
-13% -$1.02M 0.01% 1572
2023
Q3 		$8.25M Buy
880,231
+826,696
+1,544% +$11.8M 0.01% 1421
2023
Q2 		$1.31M Sell
53,535
-13,765
-20% -$346K ﹤0.01% 2922
2023
Q1 		$1.57M Buy
67,300
+22,305
+50% +$570K ﹤0.01% 2860
2022
Q4 		$1.14M Buy
44,995
+30,177
+204% +$740K ﹤0.01% 3353
2022
Q3 		$286K Buy
14,818
+6,230
+73% +$158K ﹤0.01% 4321
2022
Q2 		$219K Sell
8,588
-43,642
-84% -$1.02M ﹤0.01% 4510
2022
Q1 		$1.34M Sell
52,230
-92,572
-64% -$2.75M ﹤0.01% 3665
2021
Q4 		$6.06M Sell
144,802
-22,324
-13% -$875K 0.01% 2175
2021
Q3 		$7.27M Sell
167,126
-52,102
-24% -$2.26M 0.01% 1777
2021
Q2 		$10.4M Buy
219,228
+102,936
+89% +$4.68M 0.01% 1466
2021
Q1 		$5.96M Buy
116,292
+94,721
+439% +$5.1M 0.01% 1721
2020
Q4 		$578K Buy
+21,571
New +$701K ﹤0.01% 3321

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

D.E. Shaw & Co's VIR Position: Q1 2026 in Review

D.E. Shaw & Co increased its Vir Biotechnology (VIR) stake by 1,542% in Q1 2026, buying an estimated $6.12M and bringing the position to 817,685 shares worth $7.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

D.E. Shaw & Co first reported a position in VIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $10.4M in Q2 2021. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • D.E. Shaw & Co held 817,685 shares of Vir Biotechnology worth $7.33M as of Q1 2026.
  • D.E. Shaw & Co bought 767,893 Vir Biotechnology shares in Q1 2026, an estimated $6.12M.
  • Vir Biotechnology made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1876 holding.
  • D.E. Shaw & Co first reported a position in Vir Biotechnology in Q4 2020 and has held it in 22 quarters since.
  • D.E. Shaw & Co's Vir Biotechnology position peaked at $10.4M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.